We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+14.45%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$3.02B
AUM Growth
-$134M
(-4.3%)
Cap. Flow
-$450M
Cap. Flow
% of AUM
-14.91%
Top 10 Holdings %
Top 10 Hldgs %
49.86%
Holding
60
New
11
Increased
11
Reduced
17
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Stryker
SYK
|
+$131M |
| 2 |
Cigna
CI
|
+$111M |
| 3 |
AGN
Allergan plc
AGN
|
+$101M |
| 4 |
CVS Health
CVS
|
+$91.5M |
| 5 |
Medtronic
MDT
|
+$87.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baxter International
BAX
|
+$133M |
| 2 |
Merck
MRK
|
+$119M |
| 3 |
Thermo Fisher Scientific
TMO
|
+$114M |
| 4 |
Elevance Health
ELV
|
+$96.2M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
+$85.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Neurocrine Biosciences
NBIX
$16.8B
| $50.5M | 1.67% |
410,356
-383,599
| -48% | -$43.5M |
|
|
CERN
27
DELISTED
Cerner Corp
CERN
| $47M | 1.56% |
729,050
-32,890
| -4% | -$2.09M |
|
28
Vertex Pharmaceuticals
VRTX
$120B
| $39M | 1.29% |
202,180
-143,370
| -41% | -$25.5M |
|
|
DVAX
29
DELISTED
Dynavax Technologies
DVAX
| $38.7M | 1.28% |
3,121,469
+590,362
| +23% | +$7.99M |
|
30
Haemonetics
HAE
$3.99B
| $34.3M | 1.14% |
+299,239
| New | +$31M |
|
31
Danaher
DHR
$139B
| $30M | 1% |
311,554
-261,842
| -46% | -$23.8M |
|
|
CVRS
32
DELISTED
CORINDUS VASCULAR ROBOTICS, INC
CVRS
| $28.4M | 0.94% |
19,981,655
| – | – |
|
|
VRAY
33
DELISTED
ViewRay, Inc.
VRAY
| $23.6M | 0.78% |
+2,522,380
| New | +$24.8M |
|
34
Amneal Pharmaceuticals
AMRX
$5.95B
| $23M | 0.76% |
+1,036,110
| New | +$21.8M |
|
|
MDCO
35
DELISTED
Medicines Co
MDCO
| $20.4M | 0.68% |
682,200
-321,748
| -32% | -$12.1M |
|
|
PTE
36
DELISTED
PolarityTE, Inc. Common Stock
PTE
| $13.8M | 0.46% |
28,852
+19,069
| +195% | +$11M |
|
37
Gilead Sciences
GILD
$162B
| $10.3M | 0.34% |
+132,870
| New | +$10M |
|
38
Bio-Rad Laboratories Class A
BIO
$8.84B
| $5.08M | 0.17% |
+16,240
| New | +$5.04M |
|
39
Biogen
BIIB
$29.6B
| $4.1M | 0.14% |
+11,610
| New | +$4M |
|
40
ICU Medical
ICUI
$4.36B
| $2.94M | 0.1% |
+10,380
| New | +$3.04M |
|
|
ZSAN
41
DELISTED
Zosano Pharma Corporation
ZSAN
| $2.27M | 0.08% |
15,869
| – | – |
|
42
Amgen
AMGN
$208B
| – | – |
-51,510
| Closed | -$9.51M |
|
|
43
Baxter International
BAX
$14.2B
| – | – |
-1,800,000
| Closed | -$133M |
|
|
44
PUT
Baxter International
BAX
$14.2B
| – | – |
-200,000
| Closed | -$14.8M |
|
45
CALL
Bristol-Myers Squibb
BMY
$133B
| – | – |
-500,000
| Closed | -$27.7M |
|
|
46
Bristol-Myers Squibb
BMY
$133B
| – | – |
-488,750
| Closed | -$27M |
|
47
Centene
CNC
$30.5B
| – | – |
-586,360
| Closed | -$36.1M |
|
|
EXAS
48
DELISTED
Exact Sciences
EXAS
| – | – |
-572,240
| Closed | -$34.2M |
|
|
HOLX
49
DELISTED
Hologic
HOLX
| – | – |
-345,900
| Closed | -$13.8M |
|
|
MASI
50
DELISTED
Masimo
MASI
| – | – |
-747,040
| Closed | -$72.9M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q3 2018 Portfolio in Review
As of Q3 2018, HealthCor Management held 60 positions worth $3.02B, down 4.3% from $3.15B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
HealthCor Management withdrew a net $450M in Q3 2018, closing 19 positions and reducing 17 holdings. Its most notable exit was Baxter International, an estimated $133M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 88% a quarter earlier.
Against the trend, HealthCor Management opened a new position in Cigna worth $125M.
- HealthCor Management's largest Q3 2018 buy was Cigna: 600,000 shares worth $125M.
- HealthCor Management added most to Stryker in Q3 2018, an estimated $131M increase.
- HealthCor Management's biggest Q3 2018 reduction was Merck, cutting an estimated $119M.
- HealthCor Management fully exited Baxter International in Q3 2018, selling an estimated $133M.
- HealthCor Management's ten largest holdings make up 50% of its $3.02B portfolio in Q3 2018.
- HealthCor Management opened 11 new positions and closed 19 in Q3 2018.
- HealthCor Management's portfolio value fell 4.3% quarter-over-quarter to $3.02B.
Based on HealthCor Management's 13F filing for Q3 2018, filed 15 Nov 2018.